Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases
This pilot phase II trial studies how well pembrolizumab in combination with liver-directed therapy or Peptide Receptor Radionuclide Therapy (PRRT) works in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as, transarterial embolization (TAE), yttrium-90 microsphere radioembolization (RE), and cryoablation may help to shrink tumors that are not being directly targeted. Somatostatin receptor positive (SSTR+) well- diferentiated neuroendocrine tumors (WD-NETs) may benefit from treatment with peptide receptor radionuclide therapy (PRRT) using 177Lu DOTATATE. Giving pembrolizumab in combination with liver-directed therapy or PRRT may work better in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver.
A Pilot Study of Pembrolizumab and Liver Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
- To evaluate the best observed overall response rate (ORR) in lesion(s) not targeted for liver-directed therapy (abscopal effect) to pembrolizumab plus liver-directed therapy according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for patients with metastatic well-differentiated [World Heath Organization (WHO) grade 1 or 2] neuroendocrine tumors (NET) (WD-NETs).
- To determine the safety and tolerability of pembrolizumab in combination with liver-directed therapies in this patient population.
II. To evaluate duration of response (DOR) in patients receiving pembrolizumab in combination with liver-directed therapies.
III. To evaluate progression free survival (PFS) in subjects treated with pembrolizumab in combination with liver-directed therapies.
IV. Best observed radiographic ORR per modified RECIST (mRECIST) in lesions targeted for liver-directed therapy.
- Duration of response in lesions targeted for liver-directed therapy by mRECIST.
OUTLINE: Patients are assigned to 1 of 4 groups.
GROUP I: Patients receive pembrolizumab intravenously (IV) over 30 minutes on day 1. Treatment repeats every 21 days for up to 35 courses in the absence of disease progression or unacceptable toxicity. PRRT using 177Lu-DOTATATE(Lutathera®) will be offered to patients with somatostatin receptor positive (SSTR+) tumors with Ki-67 index > 20% (well-differentiated grade 3). Patients may have any number of liver and/or extrahepatic lesions with liver parenchyma replacement by tumor < 75%. 200±20 millicurie (mCi) of 177Lu-DOTATATE will be administered intravenously per treatment on outpatient basis. Patients will receive a total of four treatments of 177Lu-DOTATATE, administered every 8±1 weeks
GROUP II: Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest being no larger than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo transarterial embolization (TAE) over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
GROUP III: Patients receive pembrolizumab as in Group I. Patients with any number of liver lesions, largest measuring more than 5 cm, who have < 75% liver parenchyma replacement by tumors, undergo yttrium-90 microsphere radioembolization (RE) 3-15 days following the first dose of pembrolizumab.
GROUP IV: Patients receive pembrolizumab as in Group I. Patients with up to 6 liver lesions, largest being no larger than 4 cm who have < 25% liver parenchyma replacement by tumors, undergo CT-guided cryoablation over 2-3 hours, 3-7 days following the first dose of pembrolizumab.
After completion of study treatment, patients are followed up at 30 days and then every 3-6 months thereafter.
Metastatic Malignant Neoplasm in the Liver Neuroendocrine Neoplasm Neuroendocrine Tumors Neoplasms Pembrolizumab Arterial Embolization Cryoablation Peptide Receptor Radionuclide Therapy (PRRT) using 177Lu-DOTA0-Tyr3-Octreotate Yttrium-90 Microsphere Radioembolization
For people ages 18 years and up
Subject Inclusion Criteria
- Be willing and able to provide written informed consent for the trial.
- Be >= 18 years of age on day of signing informed consent.
- Have a histologically proven well-differentiated neuroendocrine tumor (WHO grade 1, grade 2, or morphologically and/or clinically well-differentiated grade 3) of any primary site, including unknown primary site.
- For group 1, only well-differentiated grade 3 tumors that demonstrate somatostatin receptor expression on Ga-68 DOTA or In-111 Octreoscans will be allowed.
- Radiographic, biochemical, or clinical evidence of tumor progression over a period of up to 12 months in at least one site.
- Group 1: At least one symptomatic and/or progressive somatostatin receptor positive (SSTR+) lesion over a period of up to 12 months or have at least one measurable lesion based on RECIST v. 1.1.
- Groups 2-4: At least one symptomatic and/or progressive liver lesion over a period of up to 12 months or have at least two measurable lesions in the liver or at least one measurable lesion in the liver and another measurable lesion elsewhere, based on RECIST v. 1.1.
- Patients must agree to have a biopsy of metastatic tissue at baseline and on treatment, and there must be a lesion that can be biopsied with acceptable clinical risk (as judged by the investigator).
- Patients with unsuccessful baseline biopsies may undergo an additional biopsy attempt (at the same or a different site, determined by the investigator).
- For patients with an intact primary and no metastatic site that can be safely biopsied, biopsy of the primary is acceptable, but must be approved by the principal investigator.
- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Scale.
- Have a life expectancy of greater than 3 months.
- Demonstrate adequate organ function.
- Absolute neutrophil count (ANC) ≥1,500 /microliters (mcL).
- Platelet count >75,000/mcL.
- Hemoglobin > 9g/dLb (For group 1 only. There is no hemoglobin cut-off level for groups 2-4).
- Serum creatinine OR Measured or calculated a creatinine clearance (GFR can also be used in place of creatinine or CrCl) ≤1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN.
- Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN.
- AST (SGOT) and ALT (SGPT) ≤ 5 X ULN.
- Albumin >2.5 mg/dL.
- International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or partial thrombin time (PTT) is within therapeutic range of intended use of anticoagulants.
- Female subject of childbearing potential should have a negative urine or serum pregnancy within 30 days prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- . Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
- . Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.
Subject Exclusion Criteria
- Has had prior thermal ablation, embolotherapy, radioembolization, or external beam radiation within 30 days of initiation of study therapy.
- Has had prior peptide receptor radionuclide therapy (group 1 only).
- Has had biliary tract intervention that resulted in compromise to the Ampulla of Vater or a biliary-enteric anastomosis (groups 2-4 only).
- Has greater than 75% liver parenchyma replacement by tumor (determined by radiologist investigator).
- Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment.
- Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.
- Has a known history of active Tuberculosis (TB) (Bacillus Tuberculosis).
- Hypersensitivity to pembrolizumab or any of its excipients.
- Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., <=Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier.
- . Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., <=Grade 1 or at baseline) from adverse events due to a previously administered agent.
- Note: Subjects with ≤ Grade 2 neuropathy are an exception to this criterion and may qualify for the study.
- Note: If subject received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.
- Concurrent somatostatin analog therapy is allowed (for control of hormone excess) provided patient has been on stable dose for at least two months and tumor progression has been documented.
- . Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
- . Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided they are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to trial treatment. This exception does not include carcinomatous meningitis which is excluded regardless of clinical stability.
- . Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- . Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
- . Has an active infection requiring systemic therapy.
- . Has liver fibrosis either determined by imaging or laboratory testing (i.e. total serum bilirubin > 1.5 times ULN, Aspartate Aminotransferase (AST) and alanine aminotransferase (ALT) > 5 times ULN, INR >1.5 times ULN, albumin < 2.0mg/dl).
- . Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
- . Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- . Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the screening visit through 120 days after the last dose of trial treatment.
- . Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
- . Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).
- . Has known active untreated Hepatitis B.
- . Has received a live vaccine within 30 days of planned start of study therapy. a. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines, and are not allowed
- University of California, San Francisco
accepting new patients
San Francisco California 94115 United States
Lead Scientist at UCSF
- Nicholas Fidelman
Nicholas Fidelman, MD, is an Associate Professor of Clinical Radiology at the University of California, San Francisco and UCSF Mount Zion. Dr. Fidelman received his medical degree from UCSF in 2002, and completed his residency in Diagnostic Radiology from UCSF in 2007, followed by a fellowship in Interventional Radiology from UCSF in 2008.
- accepting new patients
- Start Date
- Completion Date
- Nicholas Fidelman, MD
- Phase 2
- Study Type
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study. Submitting your contact information does not obligate you to participate in research.
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT03457948.